ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Approach to treatment of subacute constrictive pericarditis in adults

Approach to treatment of subacute constrictive pericarditis in adults
This figure summarizes our suggested general approach to treating subacute constrictive pericarditis in adult patients. Subacute constrictive pericarditis is generally manifested by chest pain, elevated CRP or ESR, pericardial effusion, and pericardial delayed hyperenhancement on CMR in addition to symptoms and signs of pericardial constriction. The treatment approach outlined above does not apply to patients with chronic constrictive pericarditis, which is manifested by anasarca, atrial fibrillation, hepatic dysfunction, and/or pericardial calcification. Refer to UpToDate topics on constrictive pericarditis for additional detail, including guidance on dosing for the medications in this figure and discussion of the evidence supporting their efficacy. Limited data are available on the duration of drug therapies for constrictive pericarditis. Refer to UpToDate topics also for discussion of treatment of effusive-constrictive pericarditis including pericardiocentesis and treatment of specific causes of this condition (eg, tuberculosis, neoplasm, or systemic rheumatic disease).

NSAID: nonsteroidal antiinflammatory drug; IL-1: interleukin-1; CRP: serum C-reactive protein level; ESR: erythrocyte sedimentation rate; CMR: cardiovascular magnetic resonance; CCT: cardiac computed tomography.

* For patients with relative or absolute contraindications to NSAID, a glucocorticoid is an alternative to an NSAID. In addition, it is reasonable to proceed directly to treatment with glucocorticoid plus colchicine if the patient has recently been treated with a course of an NSAID plus colchicine (eg, for treatment of acute or recurrent pericarditis).

¶ For patients with prior recurrent or incessant pericarditis, an IL-1 inhibitor is a reasonable alternative to NSAID plus colchicine or glucocorticoid plus colchicine therapy.

Δ Treatment response is assessed by evaluating symptoms and CRP (with or without repeat imaging). A good response is indicated by improvement or resolution of symptoms, reduction or normalization of the CRP, and, if assessed, improvement or resolution of inflammation on CMR or normalization of pericardial thickness on CCT or CMR.

◊ The IL-1 inhibitor used in this setting may be anakinra or rilonacept.
Graphic 141073 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟